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Introduction: The stroke prone spontaneously hypertensive rat (SHRSP) is an established model of hu-
man cardiovascular risk. We sought to characterise the uteroplacental vascular response to pregnancy in
this model and determine whether this is affected by the pre-existing maternal hypertension.
Methods: Doppler ultrasound and myography were utilised to assess uterine artery functional and
structural changes pre-pregnancy and at gestational day 18 in SHRSP (untreated and nifedipine treated)
and in the normotensive Wistar-Kyoto (WKY) rat. Maternal adaptations to pregnancy were also assessed
along with histology and expression of genes involved in oxidative stress in the placenta.
Results: SHRSP uterine arteries had a pulsatile blood ﬂow and were signiﬁcantly smaller
(70906 ± 3903 mm2 vs. 95656 ± 8524 mm2 cross-sectional area; p < 0.01), had a signiﬁcant increase in
contractile response (57.3 ± 10.5 kPa vs 27.7 ± 1.9 kPa; p < 0.01) and exhibited impaired endothelium-
dependent vasorelaxation (58.0 ± 5.9% vs 13.9 ± 4.6%; p < 0.01) compared to WKY. Despite signiﬁcant
blood pressure lowering, nifedipine did not improve uterine artery remodelling, function or blood ﬂow in
SHRSP. Maternal plasma sFLT-1/PlGF ratio (5.3 ± 0.3 vs 4.6 ± 0.1; p < 0.01) and the urinary albumin/
creatinine ratio (1.9 ± 0.2 vs 0.6 ± 0.1; p < 0.01) was increased in SHRSP vs WKY. The SHRSP placenta had
a signiﬁcant reduction in glycogen cell content and an increase in Hif1a, Sod1 and Vegf.
Discussion: We conclude that the SHRSP exhibits a number of promising characteristics as a model of
spontaneous deﬁcient uteroplacental remodelling that adversely affect pregnancy outcome, independent
of pre-existing hypertension.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In human pregnancy, the cardiovascular (CV) system undergoes
major adaptations in response to the developing fetus. A central
change in the CV system is a steady increase of 40e50% in blood
volume [1]. The resulting increase in cardiac output is accommo-
dated by angiogenesis [2] and, predominantly, the adaptation of
existing vasculature in order to stabilise blood pressure by reducing
total peripheral resistance [3]. In particular, the remodelling of the
uteroplacental vasculature plays a critical role in sustaining an
adequate blood ﬂow at the maternaleplacental interface, thus
providing the developing fetus with appropriate nutrients andand Medical Sciences, College
of Glasgow, 126 University
Small).
r Ltd. This is an open access articleoxygen. Deﬁciencies of the maternal uterine vasculature have been
shown to be present in women with gestational hypertension [4],
pre-eclampsia [5], fetal growth restriction [6] and recurrent preg-
nancy loss [7]. These conditions signiﬁcantly contribute tomaternal
and fetal morbidity andmortality worldwide. Despite the impact of
these pregnancy-related complications, there is a lack of under-
standing in the underlying pathophysiological mechanism of how
and why the uteroplacental vasculature does not remodel sufﬁ-
ciently. The ability to study these underlying mechanisms of
abnormal remodelling in human uteroplacental vasculature during
pregnancy is limited and the use of small animal models has
contributed greatly to this ﬁeld. In particular, the rat shows a
similar maternal vascular response to pregnancy [8] and exhibits
the same haemochorial placental type as humans [9]. However,
currently, there are no models which exhibit spontaneous deﬁcient
uterine artery remodelling accompanied by reduced uteroplacental
blood ﬂow without pharmacological, transgenic or surgicalunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The incidence of cardiovascular disease (CVD) in women of
child-bearing age is increasing [10]. Despite a similar percentage of
pregnancies being affected by pre-existing CVD (3e5%) [10e12] as
some forms of pregnancy-speciﬁc hypertension such as pre-
eclampsia; it has received relatively less research attention. De-
ﬁciencies in pregnancy-related vascular remodelling may be
related to pre-existing CV risk as the adaptation of the CV system
can be likened to a stress test causing these risk factors to be
manifested clinically as pregnancy induced hypertension [13]. The
stroke prone spontaneously hypertensive rat (SHRSP) is an estab-
lished model of genetic predisposition to CVD and mimics many of
the human traits observed in CVD. These rats are characterised by
spontaneous hypertension and a higher rate of cardiovascular
complications compared to the control strain; the Wistar Kyoto
(WKY) rat [14]. Previous studies have brieﬂy characterised preg-
nancy in the SHRSP [15] and have indicated that placental amino
acid transport is deﬁcient in these animals [16] however the
response of the uterine vasculature to pregnancy in the SHRSP has
not been studied. We hypothesized that pre-existing maternal CV
risk in SHRSP would result in deﬁcient remodelling of the utero-
placental vasculature in response to pregnancy. We aimed to
characterise how SHRSP and WKY responded to pregnancy by
analysing the structure and function of the uterine arteries before
and during pregnancy as well as characterising the effects this may
have on maternal and placental adaptation and fetal outcome.
Furthermore, we carried out an intervention study in SHRSP only,
using nifedipine to distinguish whether deﬁciencies in uterine
vascular remodelling present in this model were dependent upon
the presence of pre-existing hypertension.
2. Materials and methods
2.1. Animals
Female SHRSP and WKY were recruited to the study at 7 weeks
of age. All animals were housed under controlled lighting (from
0700 to 1900 h) and temperature (21 ± 3 C) and received a normal
diet (rat and mouse No.1 maintenance diet, Special Diet Services).
All animal procedures were approved by the Home Ofﬁce according
to the Animals (Scientiﬁc Procedures) Act 1886 (Project License 60/
4286). All females were age-matched and time mated at 12 weeks
of age (±4 days). Virgin animals were used at 15 weeks of age. Day
0 of pregnancy was deﬁned as the day that a coital plug was
observed indicative of successful mating having taken place.
For vascular studies, animals were split into two sub-groups
where one was used to measure blood pressure by radiotelem-
etry and allowed to progress to parturition (untreated WKY, un-
treated SHRSP and nifedipine treated SHRSP; n ¼ 6 in each group)
and the other was used for ultrasound and sacriﬁced at gestational
day (GD) 18 for ex vivo pressure and wire myography (untreated
WKY, untreated SHRSP and nifedipine treated SHRSP; n ¼ 6 in each
group). For biochemical measurements and placental histology,
untreated pregnant SHRSP andWKY rats (n¼ 8 in each group)were
sacriﬁced at GD 18. For additional fetal and placental measure-
ments untreated SHRSP (n ¼ 4) and WKY rats (n ¼ 4) were har-
vested at GD 14 and 20.
2.2. Nifedipine treatment of SHRSP
7 week old SHRSP began nifedipine treatment at 25 mg/kg/day
administered in two doses: a 10 mg/kg/day dose mixed in a 1 ml
aliquot of baby food and a 15 mg/kg/day dose in drinking water in
order to maintain lowered blood pressure throughout the 24 h
period. Stock solutions of nifedipine in drinking water wereprepared in ethanol and diluted to the appropriate concentration
with no more than a 0.8% ﬁnal ethanol concentration.
2.3. Blood pressure measurement
Blood pressure from 7 to 10 weeks was measured using tail cuff
plethysmography [17]. A radiotelemetry transmitter (calibration
accurate within ± 6 mmHg) was implanted at 10 weeks into un-
treated WKY, untreated SHRSP and nifedipine treated SHRSP
(n ¼ 6) as previously described [18]. Systolic and diastolic blood
pressure, heart rate and activity were then monitored using the
Dataquest system (Data Sciences International).
2.4. Ultrasound and Doppler analysis of the uterine arteries
Uterine artery Doppler waveform recordings were used to
assess in vivo uteroplacental blood ﬂow in untreated SHRSP,
nifedipine treated SHRSP and untreatedWKY rats. Rats were lightly
anaesthetized throughout the procedure at approximately 1.5%
isoﬂurane in oxygen. Rats were imaged trans-abdominally using an
Acuson Sequoia c256 ultrasound imager ﬁtted with a 15-MHz
linear array transducer. Peak systolic velocity (PSV) and end dia-
stolic velocity (EDV) was measured from 6 consecutive cardiac
cycles. Resistance index (RI) (RI ¼ [PSVEDV]/PSV) and S/D ratio
(PSV/EDV) were calculated.
2.5. Wire and pressure myography of the uterine arteries
Virgin and pregnant animals were age matched at the point of
sacriﬁce (GD 18). Uterine arteries were harvested from the same
area of the horn (i.e. closer to the vagina than the ovary), and which
contained the most fetuses. Arteries were not harvested from a
horn that had less than four fetuses. Arteries were dissected in
calcium free physiological salt solution (PSS) solution. Sections of
uterine artery (4.8e5.2 mm in length) were mounted on the wire
myograph (AD Instruments), normalized and subject to a wake up
procedure as previously described [19]. To establish the vessel's
contractile response, noradrenaline was added at the following
increasing concentrations: 1  109, 3  109, 1  108, 3  108,
1  107, 3  107, 1  106, 3  106, 1  105 and 3  105 M. To
determine the vessel's endothelial dependent relaxation response,
vessels were pre-constricted with 3  105 M noradrenaline fol-
lowed by the addition of carbachol at the following increasing
concentrations: 1  108, 3  108, 1  107, 3  107, 1  106,
3  106 and 1  105 M. The pressure myograph system (Danish
Myo Technology) was set up and equilibrated according to manu-
facturer's instructions. Vessels weremaintained at 37 C and 95% O2
and 5% CO2 throughout the experiment. Vessels were subject to a
pressure curve at: 10, 20, 40, 60, 80, 100 and 110 mmHg. Mea-
surements of internal (Di) and external diameter (De) were taken
after 5 min at each pressure. Wall thickness was calculated as
[(De  Di)/2]. Cross sectional area was calculated as
½ðp=4Þ  ðD2e  D2i Þ. Wall strain was calculated as [Di/De]. Wall
stress was calculated as [(133.4  pressure mmHg  Di)/2  wall
thickness] where 1 mmHg ¼ 133.4 dyn/cm2. Wall stress was then
divided by 106 to give x106 dyn per cm2.
2.6. Maternal, placental and fetal characterisation
Water intake and urine output pre-pregnancy and at different
gestational time points weremonitored by housing the animals in a
metabolic cage for 24 h. Animals were acclimatised to the meta-
bolic cage prior to use. Urine and extracted plasma were stored
at 80 C until use. Animals were sacriﬁced at GD 18 when blood
was collected by cardiac puncture and fetal and placental tissue
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the decidua, junctional zone, labyrinth zone and chorionic plate,
snap frozen in liquid nitrogen and stored at 80 C until use or
ﬁxed in 10% formalin for 24 h and processed for histology. Accurate
dissection of the placenta was conﬁrmed using qPCR markers for
the various zones (Supp. Fig. 1).
2.7. Gene expression
RNA extraction from tissues was performed using the miRNeasy
mini kit (Qiagen) according to manufacturer's instructions. Total
RNA concentration was determined by Nanodrop (Thermo Fisher
Scientiﬁc) and stored at 80 C until use. Gene expression RT-PCR
was performed using the Taqman® Reverse Transcription Kit
(Applied Biosystems) according tomanufacturer's instructions with
1 mg RNA input. The reaction was run on a Multi Block System
Satellite 0.2 Thermo Cooler (Thermo Fisher Scientiﬁc) on the
following settings: 25 C 10 min, 48 C 30 min, 95 C 5 min.
Quantitative PCR (qPCR) of Hif1a, Sod1 and Vegf was performed
using Taqman® Universal Mastermix (Applied Biosystems) and
relevant Taqman® probe (Applied Biosystems). Gene expression
protocol was run on an ABI PRISM 7900HT PCR system at the
following settings: 95 C, 15 min; followed by 40 cycles of 95 C,
15 s; 60 C, 1 min. Ct values were analysed using the 2(-delta delta
Ct) method, with dCt indicating normalisation to the housekeeper,
Gapdh. Primer details are provided in Supp. Table 1.
2.8. Histology
Tissues were prepared for histology using standard parafﬁn
process methods. 5 mm sections were mounted. Mid-sagittal sec-
tions of placenta were stained using standard haematoxylin and
eosin to assess structure. Perl's Prussian blue stainwas used to assess
free blood [20]. Brieﬂy, 4% ferrocyanide solution and 4% acidiﬁed
water were mixed immediately before incubating slides for 45 min
then counter-stainedwith 1% neutral red. Sectionswere also stained
using periodic-acid Schiff (PAS) stain to assess glycogen cell content.
Brieﬂy, equal 10 min incubations in 1% periodic acid followed by
Schiff stain (Sigma) were used. Staining and layer measurements
were quantiﬁed using ImageJ software [21] by two operators blinded
to animal identiﬁcation. Size of the placental layerswas expressed as
a percentage of the total pixels and positive staining was expressed
as the percentage of positive pixels across the tissue section.
2.9. Biochemical measurement
Plasma soluble fms-like tyrosine kinase-1 (sFLT-1) and placental
growth factor (PlGF) were measured using commercially available
kits (R&D Systems) according to manufacturer's instructions. Al-
bumin and creatinine were measured using commercially available
kits (Roche) analysed using a Roche Cobas C311 Analyser.
2.10. Statistical analysis
All data are represented as mean ± standard error of the mean
(SEM). Relevant statistical information is given in the ﬁgure legend.
3. Results
3.1. The SHRSP show deﬁcient uterine artery remodelling in
response to pregnancy
Uterine artery structure fromvirgin and pregnant (GD 18) SHRSP
and WKY rats were examined using pressure myography. WKY
uterine arteries demonstrated a pregnancy dependent (virgin vs GD18) increase in diameter and cross sectional area (Fig. 1AeC). SHRSP
virgin uterine arteries were signiﬁcantly smaller in diameter and
cross-sectional area than virgin WKY arteries (d area under the
curve: internal diameter 872.44 vs. 1064.25; external diameter
791.67 vs. 961.79). SHRSPuterine arteries also exhibited a signiﬁcant
pregnancy dependent change (with an increase in diameter and
cross-sectional area (virgin vs GD 18)); however this changewas not
to the same extent as in WKYarteries. SHRSP uterine arteries at GD
18 demonstrated a signiﬁcant decrease in both external (Fig.1A) and
internal diameter (Fig. 1B) as well as cross sectional area (Fig. 1C).
There was no signiﬁcant change in wall thickness (Fig. 1D) between
strains or between virgin and pregnant animals in either strain.Wall
stress/pressure relationship (Fig 1E) was similar between strains in
virgin animals, however at GD 18 therewas a signiﬁcant decrease in
wall stress in the SHRSP relative to pregnantWKY. Furthermore, the
stress/strain relationship (Fig. 1F) in the uterine arteries was shifted
to the right inWKYpregnant animals indicating an increase in vessel
distensibility. This rightward shift was less pronounced in SHRSP
uterine arteries indicating increased stiffness relative to the WKY.
Ex vivo wire myography in uterine arteries from pregnant WKY
demonstrated a signiﬁcant reduction in maximum contractile
response to noradrenaline (Fig. 1G) and a signiﬁcant increase in
endothelium-dependent relaxation to carbachol (Fig. 1H) when
compared to arteries from virgin WKY rats. The uterine arteries of
virgin SHRSP showed an increased maximum contractile response
to noradrenaline, and a reduced endothelium-dependent relaxa-
tion to carbachol, relative to virgin WKY (Fig. 1GeH). The con-
tractile response in uterine arteries from SHRSP at GD 18 was not
signiﬁcantly different from pre-pregnancy (Fig. 1G) and showed no
signiﬁcant increase in carbachol-mediated relaxation (Fig. 1H).
3.2. Nifedipine treatment signiﬁcantly lowers blood pressure in the
SHRSP
SHRSPwere hypertensive before and during pregnancy (average
pregnancy BP 155/112 mmHg), therefore we sought to examine
whether the observed deﬁcient uterine artery remodelling was
dependent upon the presence of elevated blood pressure. Nifedi-
pine (25 mg/kg/day), was administered in SHRSP from 7 weeks of
age to prevent the development of hypertension prior to and during
pregnancy. Blood pressure measurement by tail cuff plethysmog-
raphy (Supp. Fig. 2) followed by radiotelemetry probe implantation
at 10 weeks of age conﬁrmed that nifedipine treated SHRSP were
not hypertensive at any point during the study. Moreover, blood
pressure levels in nifedipine treated SHRSP (average pregnancy BP
132/95 mmHg) were not signiﬁcantly different from the normo-
tensive WKY rats (average pregnancy BP 117/88 mmHg) (Fig. 2).
There was a general trend for systolic blood pressure to gradu-
ally decrease in early pregnancy followed by a small increase at the
beginning of the ﬁnal week of gestation before decreasing again
prior to delivery in both the WKY and nifedipine treated SHRSP
groups. This pattern was not observed in the SHRSP where blood
pressure remained elevated and relatively stable over the course of
pregnancy until GD 16 when it also decreased until delivery. In
particular, the change in systolic blood pressure over the course of
pregnancy (Supp. Fig. 3) was at its greatest between the SHRSP and
WKY from GD 10 to 14. Heart rate was not signiﬁcantly different
between groups but activity was signiﬁcantly decreased in both
SHRSP and nifedipine treated SHRSP relative to the WKY over the
course of pregnancy (Supp. Fig. 4)
3.3. Nifedipine treatment does not improve uterine artery structure
or function in the SHRSP
Uterine artery structure from pregnant (GD 18) untreated WKY,
Fig. 1. The SHRSP exhibits deﬁcient pregnancy-associated uterine artery remodelling compared to the WKY. Isolated uterine artery structure was assessed using pressure
myography to measure external (A) and internal (B) diameter, cross-sectional area (C) and wall thickness (D) in female virgin WKY, pregnant WKY (gestational day 18), virgin SHRSP
and pregnant SHRSP (gestational day 18) (n ¼ 4e6). External and internal diameter as well as cross-sectional area was signiﬁcantly decreased in the pregnant SHRSP compared to
the WKY (**p < 0.01). Wall stress (E) was signiﬁcantly decreased in pregnant SHRSP compared to the pregnant WKY. The stress/strain curve (F) was shifted to the right upon
pregnancy in both strains but was signiﬁcantly decreased in the pregnant SHRSP. Isolated uterine artery function was also measured using wire myography in the same animals.
Maximum response to noradrenaline (G) was signiﬁcantly decreased in virgin vs. pregnant WKY (yyyp < 0.001). Virgin SHRSP had a signiﬁcantly increased maximum response to
noradrenaline relative to virgin WKY (◊◊◊ p < 0.001). Pregnant SHRSP vessels did not have a signiﬁcantly decreased response to noradrenaline vs. virgin SHRSP. Pregnant SHRSP
vessels had a signiﬁcantly increased maximum response to pregnant WKY vessels (***p < 0.001). The EC50 values for noradrenaline were not signiﬁcantly different between groups
(data not shown). Furthermore, endothelium-dependent vasorelaxation to carbachol (H) was signiﬁcantly impaired in both virgin and pregnant SHRSP (**p < 0.01 vs. WKY). Data
analysed by comparing area under the curve values using one way ANOVA and Tukey's post-hoc test.
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using pressure myography. WKY uterine arteries were signiﬁcantly
larger in diameter and cross-sectional area than arteries from
SHRSP and nifedipine treated SHRSP at GD 18. Vessels from nifed-
ipine treated SHRSP showed similar external (Fig. 3A) and internal
(Fig. 3B) diameter and cross-sectional area (Fig. 3C) compared tountreated SHRSP, therefore, uterine artery diameter in the SHRSP
was not improved when hypertension was ameliorated using
nifedipine. The passive mechanical properties of the uterine ar-
teries (Fig. 3EeF) were also not signiﬁcantly improved by nifedipine
treatment. Nifedipine treatment did not signiﬁcantly alter the
maximum contractile response to noradrenaline (Fig. 3G) or the
Fig. 2. Nifedipine signiﬁcantly inhibits blood pressure elevation in the SHRSP. Systolic (SBP) (A) and diastolic (DBP) (B) blood pressure was monitored in untreated WKY, untreated
SHRSP and nifedipine treated SHRSP (n ¼ 6) using radiotelemetry before day 0 and during pregnancy (gestational day 0 e day 21). SHRSP had signiﬁcantly increased blood pressure
compared to WKY (*p < 0.05). Nifedipine treatment signiﬁcantly reduced SHRSP blood pressure (##p < 0.01 vs. SHRSP). Data analysed by comparing area under the curve values
using one way ANOVA and Tukey's post-hoc test.
H.Y. Small et al. / Placenta 37 (2016) 34e4438endothelium-dependent relaxation response to carbachol (Fig. 3H)
in SHRSP uterine arteries.
3.4. Nifedipine treatment does not improve uterine artery blood
ﬂow or litter size in the SHRSP
The ex vivo myography data (Fig. 1) showed that there was
signiﬁcantly reduced uterine artery remodelling in the SHRSP in
response to pregnancy. We sought to examine the functional con-
sequences on in vivo uteroplacental blood ﬂow using Doppler ul-
trasound (Fig. 4A). WKY animals showed an increase in uterine
artery blood ﬂow with signiﬁcantly reduced resistance index
(Fig. 4B) and systolic/diastolic ratio (Fig. 4C) by GD 18. In contrast,
the SHRSP did not show a signiﬁcant change in resistance index
(Fig. 4B) or systolic/diastolic ratio (Fig. 4C) over the course of
pregnancy, resulting in the maintenance of a pulsatile blood ﬂow
proﬁle (Fig. 4A). Notching, an indication of increased resistance of
blood ﬂow toward the placenta, was also present in the SHRSP
(Fig. 4A). Nifedipine treated SHRSP did not show an improvement
in the Doppler proﬁle concurrent with the uterine artery myog-
raphy data. Litter size at both GD 18 and parturition, was signiﬁ-
cantly decreased in the SHRSP compared to WKY (Fig. 4DeE).
Furthermore, the incidence of resorptions was also increased in
untreated SHRSP (66%) compared to WKY (36%) and nifedipinetreated SHRSP (25%) (Table 1). The litter size was not improved by
nifedipine treatment.
3.5. SHRSP have an altered maternal response to pregnancy
In SHRSP rats at GD 18, maternal plasma sFLT-1 was signiﬁcantly
increased (Fig. 5A) whereas PlGF exhibited a trend towards a
decrease (Fig. 5B). Concurrently, sFLT-1/PlGF ratio wasmodestly but
signiﬁcantly increased in SHRSP (Fig. 5C). Maternal urine was
collected over the course of pregnancy. Albumin/Creatinine ratio
(ACR) was similar between strains pre-pregnancy (Fig. 5D). How-
ever, as pregnancy progressed the ACR signiﬁcantly increased in the
SHRSP. In contrast, ACR values in WKY rats remained relatively
stable over the course of pregnancy. Pregnancy dependent and
independent maternal weight gain was signiﬁcantly reduced in
SHRSP at GD 18 relative to WKY (Supp. Table 2 and Supp. Fig. 5).
3.6. SHRSP exhibit placental abnormalities
We found no evidence of fetal or placental weight changes be-
tween the two strains at GD 18 and both demonstrated similar fetal
and placental growth trajectories from GD 14 to GD 20 (Supp.
Fig. 6). The head:body ratio was also similar in WKY and SHRSP
fetuses at GD 20 (Supp. Fig. 6).
Fig. 3. Nifedipine treatment does not improve uterine artery structure or function in the SHRSP. Isolated uterine artery structure was assessed using pressure myography to measure
external (A) and internal (B) diameter, cross-sectional area (C) and wall thickness (D) in pregnant (gestational day 18) untreated WKY, untreated SHRSP and nifedipine treated
SHRSP (n ¼ 6). External and internal diameter as well as cross-sectional area was signiﬁcantly decreased in both untreated and nifedipine treated SHRSP (*p < 0.05 vs. WKY;
**p < 0.01 vs. WKY). Wall stress (E) was signiﬁcantly reduced and stress/strain relationship shifted to the left (F) in both untreated and nifedipine treated SHRSP. Isolated uterine
artery function was also measured using wire myography in the same animals. Maximum response to noradrenaline (G) was signiﬁcantly increased in both virgin and pregnant
SHRSP (*p < 0.05 SHRSP vs. WKY, $ p < 0.05 nifedipine vs. WKY). The EC50 values for noradrenaline were not signiﬁcantly different between groups (data not shown). Furthermore,
endothelium-dependent vasorelaxation to carbachol (H) was signiﬁcantly impaired in both untreated and nifedipine treated SHRSP (**p < 0.01 vs. WKY). Data analysed by
comparing area under the curve values using one way ANOVA and Tukey's post-hoc test.
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tissue on dissection (Fig. 6A) identiﬁed a darkened area of po-
tential haemorrhage/necrosis within the outer region of the
junctional zone in the majority of SHRSP placenta which was not
evident in the WKY. Haematoxylin and eosin staining showed
that there were no signiﬁcant size differences between the
placental layers of the two strains (Fig. 6BeC). However, periodicacid Schiff (PAS) stain revealed that the SHRSP have a signiﬁ-
cantly reduced proportion of PAS positive glycogen cells in the
junctional zone of the placenta compared to WKY (Fig. 6DeE).,
There was no signiﬁcant difference in staining in the other zones
of the placenta (Data not shown). Perl's Prussian blue staining
revealed a signiﬁcant increase in free blood principally localised
in the junctional zone of the placenta in the SHRSP compared to
Fig. 4. Nifedipine treatment does not improve in vivo uterine artery blood ﬂow or reduced litter size in the SHRSP. Uterine artery blood ﬂow was assessed using echo Doppler
analysis at gestational day 6, 12 and 18 in pregnant untreated WKY, untreated SHRSP and nifedipine treated SHRSP (n ¼ 6). Representative Doppler traces are shown in A. Resistance
index (B) and systolic/diastolic ratio (C) were signiﬁcantly decreased in WKY at gestational day 18 compared to both untreated and nifedipine treated SHRSP (**p < 0.01 vs. WKY).
Litter size, counted at gestational day 18 (D) and live-born neonates at parturition (E), were signiﬁcantly reduced in both untreated and nifedipine treated SHRSP (**p < 0.01 vs.
WKY). Statistical signiﬁcance determined using one-way ANOVA with Tukey's post-hoc test.
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(Fig. 6H), Sod1 (Fig. 6I) and Vegf (Fig. 6J) were signiﬁcantly up-
regulated in the labyrinth zone of the SHRSP placenta at GD 18.
SHRSP also showed signiﬁcantly up-regulated Hif1a and
Sod1 expression in the decidua, and Vegf was signiﬁcantlyincreased in the junctional zone.4. Discussion
This study aimed to characterise uterine artery remodelling
Table 1
Litter number and percentage resorptions in WKY, SHRSP and nifedipine treated SHRSP.
WKY untreated Untreated SHRSP SHRSP nifedipine
Litter number (GD 18) 12 ± 0.66 9 ± 0.72* 8 ± 0.85*
Litter number (parturition) 12 ± 0.71 8 ± 1.02** 8 ± 0.46**
Resorption frequency 36% 66% 25%
Resorption frequency was deﬁned as expressing the number of fetuses resorbed as a percentage of total litter size (live þ resorptions) within a single pregnancy in a
single animal. *p < 0.05 vs WKY untreated, **p < 0.01 vs WKY untreated.
H.Y. Small et al. / Placenta 37 (2016) 34e44 41during pregnancy in the setting of maternal CVD using the SHRSP
rat model. Furthermore, an intervention study was completed us-
ing nifedipine in the SHRSP rat to determine whether the presence
of pre-existing hypertension played a role in the observed deﬁcient
uterine artery remodelling.
SHRSP exhibit deﬁcient uterine artery remodelling in response
to pregnancy compared to the WKY control strain, which to our
knowledge, is the ﬁrst evidence that pre-existing CV risk can affect
the remodelling of the uteroplacental vasculature. One strength of
our study is the characterisation of pregnant uterine arteries rela-
tive to non-pregnant uterine arteries, a control which has been
identiﬁed as lacking in other studies [22]. Our results show that
non-pregnant SHRSP have smaller uterine arteries with endothelial
dysfunction compared to the WKY. Both SHRSP and WKY uterine
arteries increase in diameter and cross sectional area in response to
pregnancy but demonstrate no change in wall thickness. This is
indicative of outward hypertrophic remodelling [23], and is also
observed in human uterine arteries in response to pregnancy [24].
Measurement of the passive mechanical wall properties indicates
that pregnancy causes an increase in uterine arterial distensibility
in normal rats, however SHRSP vessels demonstrate an increased
stiffness compared to WKY. This is similar to the uterine artery
properties of other rat models of uteroplacental insufﬁciency [25]
and in women with hypertensive complications during pregnancyFig. 5. Markers of hypertensive pregnancy are increased in the SHRSP. 24 h urine samples we
18 from pregnant untreated SHRSP and WKY (n ¼ 8). Plasma sFLT-1 (A) was increased in th
PlGF ratio was signiﬁcantly increased in the SHRSP (C) (**p < 0.01 vs. WKY). Urine album
pregnancy (*p < 0.05 vs. WKY; **p < 0.01 vs. WKY). Statistical signiﬁcance determined usin[26]. In contrast to the pregnancy dependent structural changes
that were observed in both rat strains, there was a reduction in the
contractile ability of the uterine artery and an increased
endothelium-dependent relaxation response observed only in the
WKY, suggesting that SHRSP uterine arteries have an abnormal
functional response to pregnancy.
The blood pressure proﬁle in early pregnancy inWKYand SHRSP
rats shows similarities to humans. In healthy human pregnancy and
in WKY rats, blood pressure decreases towards the middle stage of
pregnancy [27]. In contrast, women who develop pregnancy
induced hypertension (PIH) do not experience this early decrease in
blood pressure [27], similar to that observed in the SHRSP rat. In
particular, the SHRSP rat exhibits the greatest blood pressure
elevation relative to the WKY from GD 10 to 14. This coincides with
the critical period of development and maturation of the rodent
placenta around day 12. The main difference in blood pressure
proﬁle between human and both rodent strains is that blood
pressure decreases towards delivery in rats whereas in humans
blood pressure returns to pre-pregnancy levels. This reduction in
blood pressure observed from GD 18 has been recorded in other
pregnancy studies using rat models [28]. It has been hypothesised
that a “hypotensive factor” is increased in the circulation of SHRSP
to induce this fall in blood pressure towards parturition [29].
The altered uterine artery remodelling in the SHRSP ratre collected at gestational days 6, 12 and 18 and plasma was collected at gestational day
e SHRSP and PlGF (B) showing a trend for decrease in the SHRSP. The plasma sFLT-1 to
in to creatinine ratio (D) was signiﬁcantly increased in the SHRSP over the course of
g Student's t-test.
Fig. 6. Placental dysfunction in the SHRSP. Once dissected from the fetus the placentas were photographed maternal side facing up and dark areas conﬁned to the edges of the
placenta were seen in SHRSP only (A). A representative H&E mid-saggital section is shown and the mesometrial triangle (Mes), decidua (Dec), junctional zone (Jx), labyrinth zone
(Lab) and chorionic plate (CP) are labelled (B). There was no signiﬁcant difference in size between the layers of the placenta (C). Periodic acid-Schiff stain was used to quantify
glycogen cell content (n ¼ 6) which was signiﬁcantly decreased in the SHRSP (DeE). Perl's Prussian blue stain was used to identify free blood (n ¼ 6) and was signiﬁcantly increased
in the SHRSP (FeG). Placentae from SHRSP and WKY (n ¼ 8) were dissected into the main layers of the placental unit: decidua (Dec), junctional zone (Jx), labyrinth zone (Lab) and
chorionic plate (CP). Genes of interest were assessed in these zones separately; the SHRSP showed an increase in Hif1a (H) and Sod1 (I) expression in both the decidua and labyrinth
whilst Vegf (J) mRNA was upregulated in the junctional zone and labyrinth. Statistical signiﬁcance determined using Student's t-test (**p < 0.01 vs. WKY; *p < 0.05 vs. WKY).
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H.Y. Small et al. / Placenta 37 (2016) 34e44 43coincides with a deﬁcient uteroplacental blood ﬂow. These obser-
vations are not improved by treatment with the clinically relevant
drug, nifedipine; even though systemic blood pressure is corrected,
indicating that deﬁcient uterine artery remodelling in the SHRSP is
not dependent upon the presence of chronic hypertension. Simi-
larly, nifedipine treatment at 22e24 weeks gestation in women
who went on to develop pre-eclampsia has been shown to signif-
icantly reduce blood pressure but did not improve abnormal uter-
ine artery blood ﬂow as assessed by Doppler ultrasound [30].
Speciﬁcally, Doppler analysis of the SHRSP uterine arteries showed
a reduced diastolic volume and the presence of notching. These are
clinical indicators of abnormal uterine artery remodelling in
humans [31,32]. Our work supports previous ﬁndings in the related
spontaneously hypertensive rat (SHR) in which placental perfusion
was reduced by 26% compared to normotensive controls [33],
furthermore this was not improved by nifedipine treatment [34].
Uteroplacental blood ﬂow has also recently been shown to be
reduced during pregnancy in salt sensitive Dahl rats, a salt-
inducible hypertensive rat strain [35].
We found that the deﬁcient uterine artery remodelling and
reduced uteroplacental perfusion in the SHRSP rat had no signiﬁ-
cant effect on fetal and placental weight but were accompanied by
abnormalities in maternal and placental physiology. During preg-
nancy, the human biomarker for PIH, sFLT-1/PlGF ratio [32] was
signiﬁcantly increased in maternal plasma in the SHRSP rat relative
to the WKY. We have found that SHRSP dams do not show pro-
teinuria when measured by bicinchoninic acid assay (BCA) (data
not shown); however ACR steadily increases over the course of
pregnancy in the SHRSP despite a similar ACR to the WKY rat pre-
pregnancy. This indicates that there may be pregnancy-related
maternal kidney dysfunction in these animals. With respect to
the fetus, previous work has shown growth restricted fetuses from
the SHR strain; however in this previous study the animals were
sacriﬁced at a later gestational age (GD 20) [36]. We did not observe
any fetal growth restriction, at GD 18 or GD 20 in the SHRSP,
indicating that fetal growth was not affected by the hypertensive
conditions in this model. We did, however, observe a reduction in
litter size consistent with previous ﬁndings in the SHRSP [15] and
an increase in the number of resorptions observed per litter in the
SHRSP which has not been previously reported. Our hypothesis is
that the reduced litter size and increased number of resorptions
observed in SHRSP rats are due to sub-optimal uteroplacental blood
ﬂow resulting from deﬁcient uterine artery remodelling. However,
at this stage, we have not determined whether these changes are a
cause or effect of the altered remodelling.
We have shown evidence of glycogen cell loss in the SHRSP
placenta, speciﬁcally in the junctional zone. As no other alterations
were observed in the other placental layers (i.e. decidua) we
conclude that this is not a result of the migration of the glycogen
cells but a depletion in the SHRSP placenta compared to WKY. The
reduction in uteroplacental perfusion in the SHRSP may cause the
placenta to utilise glycogen stores prematurely relative to the WKY.
The SHRSP had visible placental abnormalities in the darkened
outer region of the junctional zone. Perl's Prussian blue staining
conﬁrmed there was a larger proportion of free blood in the SHRSP
junctional zone; however this was not typical of placental hae-
morrhage that has been observed in other studies [37]. We
hypothesise that these darkened areas could be necrosis due to
insufﬁcient perfusion; however this is yet to be conﬁrmed. Char-
acterisation of the placenta using a candidate approach for those
genes known to be involved in human hypertensive pregnancy
[38e40] revealed that the SHRSP placenta had expression patterns
consistent with a hypoxic environment. Particularly, both Hif1a and
Sod1 were up-regulated in the maternal vascular compartment of
the decidua. However, whether the expression of these genes is acause or effect of abnormal uteroplacental perfusion is yet to be
determined.
The strengths of the SHRSP as a model of hypertensive preg-
nancy are that it is a spontaneous model which requires no genetic,
pharmacological or surgical intervention making it easier to use
with increased reproducibility. Alongside this, the deﬁcient uterine
artery remodelling and high blood pressure in SHRSP are present
during the critical time of placental development, in contrast to
many surgically induced models such as the RUPP [41], where the
placenta is already fully developed when the surgical intervention
to reduce uteroplacental blood ﬂow is performed (i.e. between GD
14e15). We propose that the pregnant SHRSP rat is a relevant
addition to existing animal models of abnormal uteroplacental
blood ﬂow and will be complimentary to models such as the RUPP.
The SHRSP rat also has pre-existing maternal CV risk and, as the
incidence of CVD is increasing among women of child bearing age
[42], this model will become increasingly clinically relevant.
Recently, a large human study has shown that maternal hyper-
tension during early pregnancy as opposed to late pregnancy, has a
greater impact upon blood pressure in the offspring [43]. This
highlights the strength of the SHRSP as a model since hypertension
is present in the early stages of pregnancy. Additionally, a recent
meta-analysis examining pregnancy in women with chronic hy-
pertension has highlighted the prominence of this problem in
Western society and the increased risk of adverse outcomes for
both mother and child [44]. The SHRSP model will allow important
pre-clinical investigations of the underlying mechanisms of
abnormal vascular adaption to pregnancy and allow us to examine
the respective contribution of pre-existing maternal CV risk factors
and chronic hypertension to this process.
In summary, we have shown that pregnant SHRSP rats have
deﬁcient uterine artery remodelling and that this is independent of
chronic hypertension. Deﬁcient uterine artery remodelling is a
common underlying cause of a number of human pregnancy dis-
orders. In our model, we have provided evidence that the altered
remodelling has functional consequences for uteroplacental blood
ﬂow and impacts upon the mother as well as the placenta. The
underlying causative factors of the spontaneous deﬁcient uterine
artery remodelling in the SHRSP rat are still to be determined but
we believe that theywill be important in highlighting the underling
mechanisms in human deﬁcient uteroplacental perfusion.
Conﬂicts of interest
None to declare.
Acknowledgements
This work was funded by studentships from the British Heart
Foundation FS/12/66/30003 (H.Y.S., S.G. and M.I.) and Medical
Research Council MR/J50032X/1 (H.M.) and funding from the
Yorkhill Children's Foundation (D.G).
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.placenta.2015.10.022.
References
[1] J.F. Clapp 3rd, B.L. Seaward, R.H. Sleamaker, J. Hiser, Maternal physiologic
adaptations to early human pregnancy, Am. J. Obstet. Gynecol. 159 (6) (1988)
1456e1460.
[2] M. Zygmunt, F. Herr, K. Munstedt, U. Lang, O.D. Liang, Angiogenesis and
vasculogenesis in pregnancy, Eur. J. Obstet. Gynecol. Reprod. Biol. 110
(Suppl. 1) (2003) S10eS18.
H.Y. Small et al. / Placenta 37 (2016) 34e4444[3] G. Osol, L.G. Moore, Maternal uterine vascular remodeling during pregnancy,
Microcirculation 21 (1) (2014) 38e47.
[4] R. Pijnenborg, J. Anthony, D.A. Davey, A. Rees, A. Tiltman, L. Vercruysse, et al.,
Placental bed spiral arteries in the hypertensive disorders of pregnancy, Br. J.
Obstet. Gynaecol. 98 (7) (1991) 648e655.
[5] I.A. Brosens, W.B. Robertson, H.G. Dixon, The role of the spiral arteries in the
pathogenesis of preeclampsia, Obstet. Gynecol. Annu. 1 (1972) 177e191.
[6] T. Todros, A. Sciarrone, E. Piccoli, C. Guiot, P. Kaufmann, J. Kingdom, Umbilical
Doppler waveforms and placental villous angiogenesis in pregnancies
complicated by fetal growth restriction, Obstet. Gynecol. 93 (4) (1999)
499e503.
[7] S. Quenby, H. Nik, B. Innes, G. Lash, M. Turner, J. Drury, et al., Uterine natural
killer cells and angiogenesis in recurrent reproductive failure, Hum. Reprod.
24 (1) (2009) 45e54.
[8] G. Osol, M. Cipolla, Pregnancy-induced changes in the three-dimensional
mechanical properties of pressurized rat uteroplacental (radial) arteries, Am.
J. Obstet. Gynecol. 168 (1 Pt 1) (1993) 268e274.
[9] M.J. Soares, D. Chakraborty, M.A. Karim Rumi, T. Konno, S.J. Renaud, Rat
placentation: an experimental model for investigating the hemochorial
maternal-fetal interface, Placenta 33 (4) (2012) 233e243.
[10] E.W. Seely, J. Ecker, Chronic hypertension in pregnancy, Circulation 129 (11)
(2014) 1254e1261.
[11] B.T. Bateman, P. Bansil, S. Hernandez-Diaz, J.M. Mhyre, W.M. Callaghan,
E.V. Kuklina, Prevalence, trends, and outcomes of chronic hypertension: a
nationwide sample of delivery admissions, Am. J. Obstet. Gynecol. 206(2)
(134) (2012) e1e8.
[12] B.M. Sibai, Chronic hypertension in pregnancy, Obstet. Gynecol. 100 (2) (2002)
369e377.
[13] N. Sattar, I.A. Greer, Pregnancy complications and maternal cardiovascular
risk: opportunities for intervention and screening? BMJ 325 (7356) (2002)
157e160.
[14] K. Okamoto, K. Yamamoto, N. Morita, Y. Ohta, T. Chikugo, T. Higashizawa, et
al., Establishment and use of the M-strain of stroke-prone spontaneously
hypertensive rat, J. Hypertens. 4 (1986) S21eS24.
[15] N. Yamada, K. Kido, T. Tamai, M. Mukai, S. Hayashi, Hypertensive effects on
pregnancy in spontaneously hypertensive rats (SHR) and stroke-prone SHR
(SHRSP), Int. J. Biol. Res. Pregnancy 2 (2) (1981) 80e84.
[16] I. Fuchi, H. Higashino, K. Noda, A. Suzuki, Y. Matsubara, Placental Naþ, Kþ
activated ATP-ase activity in SHRSP in connection with pregnancy induced
hypertension and intra-uterine growth retardation, Clin. Exp. Pharmacol.
Physiol. Suppl. 22 (1) (1995) S283eS285.
[17] R.D. Bunag, J. Butterﬁeld, Tail-cuff blood-pressure measurement without
external preheating in awake rats, Hypertension 4 (6) (1982) 898e903.
[18] N.H. Anderson, A.M. Devlin, D. Graham, J.J. Morton, C.A. Hamilton, J.L. Reid, et
al., Telemetry for cardiovascular monitoring in a pharmacological study: new
approaches to data analysis, Hypertension 33 (1 Pt 2) (1999) 248e255.
[19] A. Spiers, N. Padmanabhan, A guide to wire myography, Methods Mol. Med.
108 (2005) 91e104.
[20] J.D. Bancroft, A. Stevens, Theory and Practice of Histological Techniques,
fourth ed., Churchill Livingstone, New York, 1996.
[21] C.A. Schneider, W.S. Rasband, K.W. Eliceiri, NIH Image to ImageJ: 25 years of
image analysis, Nat. Methods 9 (7) (2012) 671e675.
[22] F.P. McCarthy, J.C. Kingdom, L.C. Kenny, S.K. Walsh, Animal models of pre-
eclampsia; uses and limitations, Placenta 32 (6) (2011) 413e419.
[23] G. Osol, M. Mandala, Maternal uterine vascular remodeling during pregnancy,
Physiol. Bethesda 24 (2009) 58e71.
[24] S.K. Palmer, S. Zamudio, C. Cofﬁn, S. Parker, E. Stamm, L.G. Moore, Quantitative
estimation of human uterine artery blood ﬂow and pelvic blood ﬂow redis-
tribution in pregnancy, Obstet. Gynecol. 80 (6) (1992) 1000e1006.
[25] M.Q. Mazzuca, M. Tare, H.C. Parkington, N.M. Dragomir, L.J. Parry,M.E. Wlodek, Uteroplacental insufﬁciency programmes vascular dysfunction
in non-pregnant rats: compensatory adaptations in pregnancy, J. Physiol. 590
(Pt 14) (2012) 3375e3388.
[26] M.D. Savvidou, C. Kaihura, J.M. Anderson, K.H. Nicolaides, Maternal arterial
stiffness in women who subsequently develop pre-eclampsia, PLoS One 6 (5)
(2011) e18703.
[27] R.C. Hermida, D.E. Ayala, A. Mojon, J.R. Fernandez, I. Alonso, I. Silva, et al.,
Blood pressure patterns in normal pregnancy, gestational hypertension, and
preeclampsia, Hypertension 36 (2) (2000) 149e158.
[28] J.N. Scott, J.C. Goecke, Proﬁle of pregnancy in young spontaneously hyper-
tensive rats, Jpn. Heart J. 25 (2) (1984) 263e266.
[29] T. Kubota, T. Yamada, Circulating hypotensive factor in pregnant spontane-
ously hypertensive rats, Clin. Exp. Pharmacol. Physiol. 8 (2) (1981) 125e132.
[30] L. Cobellis, A. De Luca, E. Pecori, A. Mastrogiacomo, L. Di Pietto, I. Iannella, et
al., Mid-trimester fetal-placental velocimetry response to nifedipine may
predict early the onset of pre-eclampsia, In Vivo 20 (1) (2006) 183e186.
[31] A.T. Papageorghiou, C.K. Yu, K.H. Nicolaides, The role of uterine artery Doppler
in predicting adverse pregnancy outcome, Best. Pract. Res. Clin. Obstet.
Gynaecol. 18 (3) (2004) 383e396.
[32] S. Verlohren, H. Stepan, R. Dechend, Angiogenic growth factors in the diag-
nosis and prediction of pre-eclampsia, Clin. Sci. Lond. 122 (2) (2012) 43e52.
[33] R.A. Ahokas, S.L. Reynolds, G.D. Anderson, J. Lipshitz, Uteroplacental blood
ﬂow in the hypertensive, term pregnant, spontaneously hypertensive rat, Am.
J. Obstet. Gynecol. 156 (4) (1987) 1010e1015.
[34] R.A. Ahokas, B.M. Sibai, W.C. Mabie, G.D. Anderson, Nifedipine does not
adversely affect uteroplacental blood ﬂow in the hypertensive term-pregnant
rat, Am. J. Obstet. Gynecol. 159 (6) (1988) 1440e1445.
[35] E.E. Gillis, J.M. Williams, M.R. Garrett, J.N. Mooney, J.M. Sasser, The dahl salt
sensitive rat is a spontaneous model of superimposed preeclampsia, Am. J.
Physiol. Regul. Integr. Comp. Physiol. (2015) ajpregu 00377 2014.
[36] B.M. Johnston, Fetal growth retardation and increased placental weight in the
spontaneously hypertensive rat, Reprod. Fertil. Dev. 7 (3) (1995) 639e645.
[37] L. Liu, G. Zhao, H. Fan, X. Zhao, P. Li, Z. Wang, et al., Mesenchymal stem cells
ameliorate Th1-induced pre-eclampsia-like symptoms in mice via the sup-
pression of TNF-alpha expression, PLoS One 9 (2) (2014) e88036.
[38] A. Rajakumar, H.M. Brandon, A. Daftary, R. Ness, K.P. Conrad, Evidence for the
functional activity of hypoxia-inducible transcription factors overexpressed in
preeclamptic placentae, Placenta 25 (10) (2004) 763e769.
[39] R. Trollmann, K. Amann, E. Schoof, E. Beinder, D. Wenzel, W. Rascher, et al.,
Hypoxia activates the human placental vascular endothelial growth factor
system in vitro and in vivo: up-regulation of vascular endothelial growth
factor in clinically relevant hypoxic ischemia in birth asphyxia, Am. J. Obstet.
Gynecol. 188 (2) (2003) 517e523.
[40] J. Vanderlelie, K. Venardos, V.L. Clifton, N.M. Gude, F.M. Clarke, A.V. Perkins,
Increased biological oxidation and reduced anti-oxidant enzyme activity in
pre-eclamptic placentae, Placenta 26 (1) (2005) 53e58.
[41] J. Li, B. LaMarca, J.F. Reckelhoff, A model of preeclampsia in rats: the reduced
uterine perfusion pressure (RUPP) model, Am. J. Physiol. Heart Circ. Physiol.
303 (1) (2012) H1eH8.
[42] V. Regitz-Zagrosek, C. Gohlke-Barwolf, B. Iung, P.G. Pieper, Management of
cardiovascular diseases during pregnancy, Curr. Probl. Cardiol. 39 (4e5)
(2014) 85e151.
[43] J.R. Staley, J. Bradley, R.J. Silverwood, L.D. Howe, K. Tilling, D.A. Lawlor, et al.,
Associations of blood pressure in pregnancy with offspring blood pressure
trajectories during childhood and adolescence: ﬁndings from a prospective
study, J. Am. Heart Assoc. 4 (5) (2015).
[44] K. Bramham, B. Parnell, C. Nelson-Piercy, P.T. Seed, L. Poston, L.C. Chappell,
Chronic hypertension and pregnancy outcomes: systematic review and meta-
analysis, BMJ 348 (2014) g2301.
